Wu D. et al. [49] reported that activation of the PD-1/PD-L1 pathway using sPD-L1 could improve the imbalance of Th1/Th2 and Treg/Th17 immune cells in ITP patients. This evidence concerns the gene SPDL1 and autoimmune thrombocytopenic purpura.